Your activity: 2 p.v.

Amoxicillin: Drug information

Amoxicillin: Drug information
(For additional information see "Amoxicillin: Patient drug information" and see "Amoxicillin: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • AG-Amoxicillin;
  • APO-Amoxi;
  • APO-Amoxi Sugar Free;
  • Auro-Amoxicillin;
  • DOM-Amoxicillin;
  • JAMP-Amoxicillin;
  • MYLAN-Amoxicillin [DSC];
  • Novamoxin;
  • PMS-Amoxicillin;
  • Polymox;
  • PRO Amox-500;
  • PRO-Amox-250
Pharmacologic Category
  • Antibiotic, Penicillin
Dosing: Adult

Note: Amoxicillin 775 mg ER tablets (brand and generic) have been discontinued in the United States for >1 year.

Note: Unless otherwise specified, all dosing recommendations are based on IR product formulations.

Usual dosage range:

Immediate release: Oral: 500 mg to 1 g every 8 to 12 hours.

Extended release: Oral: 775 mg once daily.

Actinomycosis

Actinomycosis (off-label use):

Note: For initial therapy of mild infection or step-down therapy following parenteral treatment of severe infection.

Oral: 500 mg 3 to 4 times daily or 1 g 3 times daily (Ref); higher doses of 4 to 6 g/day in divided doses have been utilized in case reports (Ref). Optimal duration is uncertain; some experts suggest total durations of 2 to 6 months for mild infection and 6 to 12 months for severe or extensive infection (Ref).

Anthrax

Anthrax (alternative agent [susceptible strains only]) (off-label use):

Note: Consult public health officials for event-specific recommendations. A high index of suspicion for emergent beta-lactam resistance during therapy is warranted (Ref).

Inhalational exposure postexposure prophylaxis (PEP): Oral: 1 g every 8 hours (Ref); duration depends on anthrax vaccine status and series completion, age, immune status, and pregnancy/breastfeeding status. For those who have not previously received anthrax vaccine, duration ranges from 42 to 60 days (Ref).

Note: Anthrax vaccine should also be administered to exposed individuals (Ref)

Cutaneous, without systemic involvement, treatment: Oral: 1 g every 8 hours; duration is 7 to 10 days after naturally acquired infection and 60 days following biological weapon-related event. Note: Patients with extensive edema or cutaneous lesions of the head or neck should be treated with a parenteral regimen recommended for systemic involvement (Ref).

Asplenia, prophylaxis against bacterial infection in select high-risk patients

Asplenia, prophylaxis against bacterial infection in select high-risk patients (off-label use): Oral: Based on expert opinion: 500 mg twice daily. Duration varies based on patient-specific factors (Ref).

Bronchiectasis

Bronchiectasis (off-label use):

Treatment of pulmonary exacerbations in patients without beta-lactamase-positive H. influenzae or Pseudomonas aeruginosa: Oral: 500 mg 3 times daily (Ref) or 1 g 3 times daily (Ref) for up to 14 days (Ref).

Prevention of pulmonary exacerbations: Oral: 500 mg twice daily; dosing based on expert opinion (Ref). Note: Recommended for patients with ≥3 exacerbations per year who are not colonized with P. aeruginosa and not candidates for long-term macrolide therapy (Ref).

Cervical infection in pregnancy due to Chlamydia trachomatis

Cervical infection in pregnancy due to Chlamydia trachomatis (alternative agent) (off-label use):

Note: Reserve for patients who are pregnant who cannot use preferred agents (Ref)

Oral: 500 mg 3 times daily for 7 days with test of cure ≥4 weeks after treatment (Ref).

Endocarditis, prophylaxis

Endocarditis, prophylaxis (dental or invasive respiratory tract procedures) (off-label use): Oral: 2 g 30 to 60 minutes before procedure; if inadvertently not given prior to the procedure, may be administered up to 2 hours after the procedure. Note: Reserve for select situations (cardiac condition with the highest risk of adverse endocarditis outcomes and procedure likely to result in bacteremia with an organism that can cause endocarditis) (Ref).

Helicobacter pylori eradication

Helicobacter pylori eradication: Oral:

Clarithromycin triple regimen: Amoxicillin 1 g twice daily in combination with clarithromycin 500 mg twice daily, plus a standard-dose or double-dose proton pump inhibitor; continue regimen for 14 days. Note: Avoid use in patients with risk factors for macrolide resistance (eg, prior macrolide exposure or local clarithromycin resistance rates ≥15%, which is assumed in the United States) (Ref).

Concomitant regimen: Amoxicillin 1 g twice daily in combination with clarithromycin 500 mg twice daily, either metronidazole or tinidazole 500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily; continue regimen for 10 to 14 days (Ref).

Sequential regimen (alternative regimen): Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; followed by clarithromycin 500 mg twice daily, either metronidazole or tinidazole 500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; some experts prefer the 10-day regimen due to the lack of data showing superiority of the 14-day sequential regimen in North America (Ref)

Hybrid regimen (alternative regimen): Amoxicillin 1 g twice daily, plus a standard-dose proton pump inhibitor twice daily for 7 days; followed by amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, either metronidazole or tinidazole 500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily for 7 days (Ref).

Levofloxacin triple regimen (salvage regimen): Amoxicillin 750 mg 3 times daily in combination with a double-dose proton pump inhibitor twice daily plus levofloxacin 500 mg once daily; continue regimen for 14 days (Ref).

High-dose dual therapy (alternative salvage regimen): Amoxicillin 750 mg 4 times daily or 1 g 3 times daily; in combination with a double-dose proton pump inhibitor twice daily for 14 days (Ref).

Lyme disease

Lyme disease (Borrelia spp. infection) (off-label use):

Erythema migrans: Oral: 500 mg 3 times daily for 14 days (Ref).

Carditis (initial therapy for mild disease [first-degree atrioventricular block with PR interval <300 msec] or step-down therapy after initial parenteral treatment for more severe disease once PR interval <300 msec): Oral: 500 mg 3 times daily for 14 to 21 days (Ref).

Arthritis without neurologic involvement: Oral: 500 mg 3 times daily for 28 days (Ref).

Otitis media, acute

Otitis media, acute (alternative agent):

Note: Some experts recommend amoxicillin/clavulanate over amoxicillin alone due to the frequency of otopathogens that produce beta-lactamases (eg, H. influenzae, Moraxella catarrhalis) (Ref).

Oral: 500 mg every 8 hours or 875 mg every 12 hours (Ref). Some experts use 1 g every 8 hours for patients at high risk of severe infection or resistant Streptococcus pneumoniae. Duration is 5 to 7 days for mild to moderate infection and 10 days for severe infection (Ref).

Periodontitis, severe, plaque-associated

Periodontitis, severe, plaque-associated (off-label use): Oral: 500 mg every 8 hours in combination with metronidazole for 14 days or until clinical resolution, whichever is longer; use in addition to periodontal debridement (Ref).

Pneumonia, community acquired

Pneumonia, community acquired:

Empiric therapy, outpatient (patients without comorbidities or risk factors for antibiotic-resistant pathogens):

Oral: 1 g 3 times daily (Ref); some experts prefer use of amoxicillin in combination with an antibiotic that targets atypical pathogens (Ref).

Oral step-down therapy following initial parenteral therapy, inpatient:

Oral: 1 g 3 times daily; some experts use lower doses (500 mg 3 times daily or 875 mg twice daily) for patients without risk factors for drug-resistant S. pneumoniae (eg, age <65 years without comorbidities) (Ref).

Duration is for a minimum of 5 days; patients should be clinically stable with normal vital signs before therapy is discontinued (Ref).

Prosthetic joint infection, chronic suppression

Prosthetic joint infection, chronic suppression (off-label use):

Note: For infection caused by beta-hemolytic streptococci, penicillin-susceptible Enterococcus spp., or Cutibacterium spp. (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis).

Oral: 500 mg 3 times daily (Ref); duration depends on patient-specific factors (Ref).

Rhinosinusitis, acute bacterial

Rhinosinusitis, acute bacterial:

Note: In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (Ref). For initial therapy of nonsevere infection in patients without risk factors for pneumococcal resistance or poor outcome (eg, ≥65 years of age, recent hospitalization or antibiotic use, multiple comorbidities, high endemic resistance) (Ref).

Oral: 500 mg every 8 hours or 875 mg every 12 hours for 5 to 7 days (Ref).

Skin and soft tissue infection

Skin and soft tissue infection:

Erysipelas, treatment of mild infection or step-down therapy after initial parenteral therapy:

Oral: 500 mg 3 times daily or 875 mg twice daily; total duration is 5 days, with extension to 14 days for slow response, severe infection, or immunosuppression (Ref).

Erysipeloid (localized cutaneous Erysipelothrix rhusiopathiae infection):

Oral: 500 mg 3 times daily for 5 to 10 days (Ref).

Streptococcal pharyngitis

Streptococcal pharyngitis (group A): Oral: 500 mg twice daily or 1 g once daily for 10 days (Ref).

Extended release: 775 mg once daily for 10 days.

Urinary tract infection

Urinary tract infection:

Note: Not recommended for empiric therapy given decreased efficacy compared to first-line agents and high prevalence of resistance (Ref).

Asymptomatic bacteriuria (≥105 CFU per mL) in pregnancy (eg, group B Streptococcus): Oral: 500 mg every 8 hours or 875 mg every 12 hours for 4 to 7 days (Ref).

Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection) due to Enterococcus spp.: Oral: 500 mg every 8 hours or 875 mg every 12 hours for 5 days (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

Oral: Immediate release:

Amoxicillin Dose Adjustments in Kidney Impairment

GFR (mL/minute)

If the normal recommended dose is 250 to 500 mg every 8 hoursa

If the normal recommended dose is 875 mg to 1 g every 12 hoursb

If the normal recommended dose is 1 g every 8 hoursb,c

aGolightly 2013; Szeto 2017; manufacturer's labeling; expert opinion

bExpert opinion

cKeller 2015

dDialyzable (30% to 47% with low flux filters [Davies 1988; Francke 1979]). If utilizing a 24-hour dosing interval, administer dose after dialysis or give an additional dose after dialysis on dialysis days.

≥30

No dosage adjustment necessary

No dosage adjustment necessary

No dosage adjustment necessary

10 to 30

250 to 500 mg every 12 hours

500 mg every 12 hours

1 g every 12 hours

<10

250 to 500 mg every 12 to 24 hours

500 mg every 12 to 24 hours

500 mg every 12 hours

Hemodialysis, intermittent (thrice weekly)d

250 to 500 mg every 12 to 24 hours

500 mg every 12 to 24 hours

500 mg every 12 hours

Peritoneal dialysis

250 to 500 mg every 12 hours

500 mg every 12 hours

500 mg every 12 hours

Oral: Extended release:

CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

CrCl <30 mL/minute: Not recommended.

Hemodialysis, intermittent (thrice weekly): Not recommended.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Pediatric

(For additional information see "Amoxicillin: Pediatric drug information")

Note: Unless otherwise specified, all pediatric dosing recommendations are based on immediate-release product formulations (oral suspension, chewable tablet, tablet, and capsule). Amoxicillin 775 mg ER tablets (brand [Moxatag] and generic) have been discontinued in the US for >1 year.

General dosing, susceptible infection:

Mild to moderate infection:

Infants ≤3 months: Oral: 25 to 50 mg/kg/day in divided doses every 8 hours (Ref). Note: Manufacturer's labeling recommends a maximum daily dose of 30 mg/kg/day divided into 2 doses per day for this age group.

Infants >3 months, Children, and Adolescents:

AAP recommendations (Ref): Oral: 25 to 50 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg/dose.

Manufacturer's labeling: Oral: 20 to 40 mg/kg/day in divided doses every 8 hours (maximum dose: 500 mg/dose) or 25 to 45 mg/kg/day in divided doses every 12 hours (maximum dose: 875 mg/dose).

Severe infection: Infants, Children, and Adolescents: Oral: 80 to 90 mg/kg/day divided every 12 hours; a maximum dose has not been established; however, some experts suggest a maximum daily dose of 4,000 mg/day (Ref).

Anthrax

Anthrax:

Cutaneous, without systemic involvement: Infants, Children, and Adolescents: Oral: 75 mg/kg/day in 3 divided doses. Maximum dose: 1,000 mg/dose. Duration of therapy: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related exposure (Ref).

Inhalational, postexposure prophylaxis: Infants, Children, and Adolescents: Oral: 75 mg/kg/day in divided doses every 8 hours for 60 days after exposure; maximum dose: 1,000 mg/dose (Ref).

Catheter, exit-site or tunnel infection

Catheter (peritoneal dialysis), exit-site or tunnel infection: Infants, Children, and Adolescents: Oral: 10 to 20 mg/kg once daily; maximum dose: 1,000 mg/dose (Ref).

Endocarditis, prophylaxis

Endocarditis, prophylaxis: Note: AHA guidelines (Ref) limit the use of prophylactic antibiotics to patients at the highest risk for infective endocarditis (IE) or adverse outcomes (eg, prosthetic heart valves, patients with previous IE, unrepaired cyanotic congenital heart disease, repaired congenital heart disease with prosthetic material or device during first 6 months after procedure, repaired congenital heart disease with residual defects at the site or adjacent to site of prosthetic patch or device, heart transplant recipients with cardiac valvulopathy):

Dental or oral procedures or respiratory tract procedures (eg, tonsillectomy, adenoidectomy): Infants, Children, and Adolescents: Oral: 50 mg/kg 30 to 60 minutes before procedure; maximum dose: 2,000 mg/dose (Ref).

Helicobacter pylori eradication

Helicobacter pylori eradication: Limited data available: Note: Use as part of an appropriate combination regimen; usual duration of therapy is 14 days (Ref).

Standard-dose regimen:

Weight-directed dosing: Children and Adolescents: Oral: 25 mg/kg/dose twice daily; maximum dose: 1,000 mg/dose (Ref).

Fixed dosing (Ref): Children and Adolescents:

15 to <25 kg: Oral: 500 mg twice daily.

25 to <35 kg: Oral: 750 mg twice daily.

≥35 kg: Oral: 1,000 mg twice daily.

High-dose regimen:

Note: For use in combination with a proton pump inhibitor and metronidazole when susceptibility is unknown or when H. pylori isolate is resistant to clarithromycin AND metronidazole. Fixed (weight-band) dosing based on a target dose of ~75 mg/kg/day divided twice daily; maximum dose reported: 100 mg/kg/day divided twice daily (Ref).

Children and Adolescents (Ref).

15 to <25 kg: Oral: 750 mg twice daily.

25 to <35 kg: Oral: 1,000 mg twice daily.

≥35 kg: Oral: 1,500 mg twice daily.

Lyme disease

Lyme disease ( Borrelia spp. infection): Infants, Children, and Adolescents: Oral: 50 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg/dose. Duration of therapy depends on clinical syndrome; treat erythema migrans and borrelial lymphocytoma for 14 days, carditis for 14 to 21 days, arthritis (initial, recurrent, or refractory) for 28 days, and acrodermatitis chronica atrophicans for 21 to 28 days (Ref).

Otitis media, acute

Otitis media, acute (AOM):

High-dose regimen: Note: Preferred in the United States and when activity against penicillin nonsusceptible Streptococcus pneumoniae is desired (Ref).

Infants ≥3 months and Children: Oral: 80 to 90 mg/kg/day in divided doses every 12 hours. Maximum dose has not been established for AOM; however, 4,000 mg/day has been suggested (Ref).

Standard-dose regimen: Note: Only for use in areas where rates of penicillin nonsusceptible S. pneumoniae are known to be low or if an isolated pathogen is penicillin-susceptible (Ref).

Infants ≥3 months and Children: Oral: 40 to 50 mg/kg/day in divided doses every 8 to 12 hours. Maximum daily dose: 1,500 mg/day (Ref).

Duration of therapy: For patients with severe or recurrent AOM, tympanic membrane perforation, or who are <2 years of age, treat for 10 days; for patients ≥2 years of age with mild to moderate, nonrecurrent disease without tympanic membrane perforation, shorter durations of 5 to 7 days may be sufficient (Ref).

Peritonitis, prophylaxis for patients requiring invasive dental procedures

Peritonitis (peritoneal dialysis), prophylaxis for patients requiring invasive dental procedures: Infants, Children, and Adolescents: Oral: 50 mg/kg administered 30 to 60 minutes before dental procedure; maximum dose: 2,000 mg/dose (Ref).

Pneumonia, community-acquired

Pneumonia, community-acquired: Infants ≥3 months, Children, and Adolescents:

Empiric therapy for presumed bacterial pneumonia: Oral: 90 mg/kg/day in divided doses every 12 hours; maximum daily dose: 4,000 mg/day (Ref).

Group A Streptococcus, mild infection or step-down therapy: Oral: 50 to 75 mg/kg/day in divided doses every 12 hours; maximum daily dose: 4,000 mg/day (Ref).

Haemophilus influenzae, mild infection or step-down therapy: Oral: 75 to 100 mg/kg/day in divided doses every 8 hours; maximum daily dose: 4,000 mg/day (Ref).

Streptococcus pneumonia, mild infection or step-down therapy (penicillin MIC ≤2 mcg/mL): Oral: 90 mg/kg/day in divided doses every 12 hours or 45 mg/kg/day in divided doses every 8 hours; maximum daily dose: 4,000 mg/day (Ref).

Streptococcus pneumonia, relatively resistant (penicillin MIC = 2 mcg/mL): Oral: 90 to 100 mg/kg/day in divided doses every 8 hours; dosing based on pharmacokinetic modeling; Monte Carlo simulations show that this dose provides optimal lung exposures to increase efficacy (Ref).

Pneumococcal infection prophylaxis for anatomic or functional asplenia

Pneumococcal infection prophylaxis for anatomic or functional asplenia [eg, sickle cell disease (SCD)] (Ref):

Before 2 months of age (or as soon as SCD is diagnosed or asplenia occurs) through 5 years of age: Oral: 20 mg/kg/day in divided doses every 12 hours; maximum dose: 250 mg/dose.

Children ≥6 years and Adolescents: Oral: 250 mg every 12 hours; Note: The decision to discontinue penicillin prophylaxis after 5 years of age in children who have not experienced invasive pneumococcal infection and have received recommended pneumococcal immunizations is patient and clinician dependent.

Rhinosinusitis, acute bacterial; uncomplicated

Rhinosinusitis, acute bacterial; uncomplicated: Note: AAP guidelines recommend amoxicillin as first-line empiric therapy for pediatric patients 1 to 18 years with uncomplicated cases and where resistance is not suspected; however, the IDSA guidelines consider amoxicillin/clavulanate as the preferred therapy (Ref):

Low dose: Children ≥2 years and Adolescents: Oral: 45 mg/kg/day in divided doses every 12 hours; Note: Only use for uncomplicated, mild to moderate infections in children who do not attend daycare and who have not received antibiotics within the last month (Ref).

High dose (use reserved for select patients; see Note): Children ≥2 years and Adolescents: Oral: 80 to 90 mg/kg/day in divided doses every 12 hours; maximum dose: 2,000 mg/dose; Note: Should only use for mild to moderate infections in children who do not attend daycare and who have not received antibiotics within the last month and live in communities with a high prevalence of nonsusceptible S. pneumoniae resistance (Ref).

Streptococcus, group A; pharyngitis/tonsillitis

Streptococcus, group A; pharyngitis/tonsillitis:

Immediate release (oral suspension, chewable tablets, tablets, and capsules): Children and Adolescents: Oral: 50 mg/kg/day once daily or in divided doses every 12 hours for 10 days; maximum daily dose: 1,000 mg/day (Ref).

Extended-release tablets: Children ≥12 years and Adolescents: Oral: 775 mg once daily for 10 days.

Urinary tract infection, prophylaxis

Urinary tract infection, prophylaxis (hydronephrosis, vesicoureteral reflux): Infants ≤2 months: Oral: 10 to 15 mg/kg once daily; some suggest administration in the evening (drug resides in bladder longer); Note: Due to resistance, amoxicillin should not be used for prophylaxis after 2 months of age (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Ref): Oral:

Immediate release: Infants, Children, and Adolescents:

Mild to moderate infection: Dosing based on 25 to 50 mg/kg/day divided every 8 hours:

GFR >30 mL/minute/1.73 m2: No adjustment required

GFR 10 to 29 mL/minute/1.73 m2: 8 to 20 mg/kg/dose every 12 hours

GFR <10 mL/minute/1.73 m2: 8 to 20 mg/kg/dose every 24 hours

Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 8 to 20 mg/kg/dose every 24 hours; give after dialysis

Peritoneal dialysis: 8 to 20 mg/kg/dose every 24 hours

Severe infection (high dose): Dosing based on 80 to 90 mg/kg/day divided every 12 hours:

GFR >30 mL/minute/1.73 m2: No adjustment required

GFR 10 to 29 mL/minute/1.73 m2: 20 mg/kg/dose every 12 hours; do not use the 875 mg tablet

GFR <10 mL/minute/1.73 m2: 20 mg/kg/dose every 24 hours; do not use the 875 mg tablet

Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 20 mg/kg/dose every 24 hours; give after dialysis

Peritoneal dialysis: 20 mg/kg/dose every 24 hours

Extended release: Children ≥12 years and Adolescents: CrCl <30 mL/minute: Not recommended

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 250 mg, 500 mg

Suspension Reconstituted, Oral:

Generic: 125 mg/5 mL (80 mL, 100 mL, 150 mL); 200 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (80 mL, 100 mL, 150 mL); 400 mg/5 mL (50 mL, 75 mL, 100 mL)

Tablet, Oral:

Generic: 500 mg, 875 mg

Tablet Chewable, Oral:

Generic: 125 mg, 250 mg

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Polymox: 250 mg, 500 mg

Generic: 250 mg, 500 mg

Suspension Reconstituted, Oral:

Polymox: 125 mg/5 mL (150 mL); 250 mg/5 mL (150 mL)

Generic: 125 mg/5 mL (15 mL, 75 mL, 100 mL, 150 mL); 250 mg/5 mL (75 mL, 100 mL, 150 mL)

Tablet Chewable, Oral:

Generic: 125 mg [DSC], 250 mg

Product Availability

Amoxicillin 775 mg ER tablets (brand and generic) have been discontinued in the United States for >1 year.

Administration: Adult

Oral: Administer around-the-clock to promote less variation in peak and trough serum levels.

Extended release: Administer within 1 hour of finishing a meal; do not chew or crush tablet.

Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation.

Suspension: Shake well before use; may be mixed with formula, milk, fruit juice, water, ginger ale, or cold drinks; administer dose immediately after mixing.

Administration: Pediatric

Oral:

Immediate release: May be administered on an empty or full stomach; may be mixed with small amount of formula, milk, cold drink, or juice; administer dose immediately after mixing; shake suspension well before use.

Extended release: Take within 1 hour of finishing a meal; do not chew or crush tablet.

Use: Labeled Indications

Ear, nose, and throat infections (pharyngitis/tonsillitis, otitis media):

Immediate release: Treatment of infections due to beta-lactamase-negative Streptococcus spp. (alpha- and beta-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae.

Extended release: Treatment of tonsillitis and/or pharyngitis due to Streptococcus pyogenes in adults and pediatric patients ≥12 years of age.

Helicobacter pylori eradication: Immediate release: Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence as a component of combination therapy in patients with active or 1-year history of duodenal ulcer disease.

Lower respiratory tract infections (including pneumonia): Immediate release: Treatment of infections of the lower respiratory tract due to beta-lactamase-negative Streptococcus spp. (alpha- and beta-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.

Rhinosinusitis, acute bacterial: Immediate release: Treatment of infections due to beta-lactamase-negative Streptococcus spp. (alpha- and beta-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae.

Skin and skin structure infections: Immediate release: Treatment of infections of the skin and skin structure due to beta-lactamase-negative Streptococcus spp. (alpha- and beta-hemolytic strains only), Staphylococcus spp., or Escherichia coli.

Urinary tract infection: Immediate release: Treatment of infections of the genitourinary tract due to beta-lactamase-negative E.coli, Proteus mirabilis, or Enterococcus faecalis.

Use: Off-Label: Adult

Actinomycosis; Anthrax; Asplenia, prophylaxis against bacterial infection in high-risk patients; Bronchiectasis; Cervical infection in pregnancy due to Chlamydia trachomatis; Endocarditis, prophylaxis; Lyme disease (Borrelia spp. infection); Periodontitis, severe, plaque-associated; Prosthetic joint infection, chronic suppression

Medication Safety Issues
Sound-alike/look-alike issues:

Amoxicillin may be confused with amoxapine, Augmentin

Amoxil may be confused with amoxapine

International issues:

Fisamox [Australia] may be confused with Fosamax brand name for alendronate [US, Canada, and multiple international markets] and Vigamox brand name for moxifloxacin [US, Canada, and multiple international markets]

Limoxin [Mexico] may be confused with Lanoxin brand name for digoxin [US, Canada, and multiple international markets]; Lincocin brand name for lincomycin [US, Canada, and multiple international markets]

Zimox: Brand name for amoxicillin [Italy], but also the brand name for carbidopa/levodopa [Greece]

Zimox [Italy] may be confused with Diamox which is the brand name for acetazolamide [Canada and multiple international markets]

Adverse Reactions (Significant): Considerations
Antibiotic-associated (non–Clostridioides difficile) diarrhea

GI effects range from antibiotic-associated [non–Clostridioides difficile] diarrhea (AAD), nausea, and vomiting. Most cases of AAD are mild and self-limiting. However, Clostridioides difficile may account for as many as >20% of cases in children, adolescents, and adults (discussed separately) (Ref). Diarrhea is less common with amoxicillin or ampicillin alone than with amoxicillin/clavulanic acid (Ref).

Mechanism: Dose- and time-related; antibiotic disruption of indigenous gut microbiota (Ref).

Onset: Varied; mean time to onset of AAD is 3 to 18 days for adult patients and 2 to 6 days for pediatric patients. The majority of AAD cases occur during (versus after) antibiotic therapy in pediatric patients (Ref).

Risk factors:

• High-dose amoxicillin regimens

• Longer duration of therapy (Ref)

• Longer length of hospitalization or ICU stay (Ref)

• Age (younger pediatric patients <2 years and older adults) (Ref)

• Longer duration of proton pump inhibitor use (Ref)

• Parenteral nutrition (Ref)

• Combined administration of antibiotics (Ref)

Clostridioides difficile diarrhea

Clostridioides difficile infection (CDI) has occurred, including Clostridioides difficile associated diarrhea (CDAD) and Clostridioides difficile colitis.

Mechanism: Dose- and time-related; related to cumulative antibiotic exposure. Amoxicillin may cause disruption of the intestinal microbiota resulting in the overgrowth of pathogens, such as C. difficile (Ref).

Onset: Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (Ref).

Risk factors:

• Antibiotic exposure (highest risk factor), especially prolonged use (Ref)

• Type of antibiotic (Ref)

• Long durations in a hospital or other health care setting (recent or current) (Ref)

• Older adults (Ref)

• Immunocompromised conditions (Ref)

• A serious underlying condition (Ref)

• GI surgery/manipulation (Ref)

• Antiulcer medications (eg, proton pump inhibitors, H2 blockers) (Ref)

• Chemotherapy (Ref)

Hypersensitivity and immunologic reactions (immediate and delayed)

Hypersensitivity and immunologic reactions (immediate and delayed) range from skin rash to rare cases of anaphylaxis in adult and pediatric patients (Ref). Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome and toxic epidermal necrolysis (Ref), drug rash with eosinophilia and systemic symptoms (DRESS) (Ref), and acute generalized exanthematous pustulosis (Ref) have been reported. Aseptic meningitis has also been documented (Ref).

Mechanism: Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) are IgE-mediated. Delayed hypersensitivity reactions, such as maculopapular rash and SCARs, are T-cell-mediated (Ref). Amoxicillin may trigger a flare of DRESS caused by other drugs, such as carbamazepine and allopurinol (Ref), possibly through reactivation of HHV-6 (Ref).

Onset: Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (Ref). Delayed hypersensitivity reactions: Maculopapular rash reactions: Intermediate; occur 7 to 10 days after initiation (Ref). Other reactions (including SCARs): Varied; occur after days to 8 weeks after initiation (Ref).

Risk factors:

• Cross-reactivity between penicillins and cephalosporins and among cephalosporins is mostly related to side chain similarity (Ref). For cephalexin, ampicillin and amoxicillin share identical or similar side chains, respectively, and cross-reactions have been reported (Ref). Additionally, cross-reactivity between benzylpenicillin and aminopenicillins (eg, amoxicillin, ampicillin) may occur (Ref).

• Viral infections (eg, Epstein-Barr virus [infectious mononucleosis], cytomegalovirus, HHV 6 and 7) (Ref)

• Epstein-Barr virus (EBV): Reported incidence of skin rash is higher in patients with an acute EBV infection concomitantly treated with amoxicillin (Ref), although not all studies have shown similar results (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Gastrointestinal: Diarrhea (2%) (table 1), nausea (1%) (table 2)

Amoxicillin: Adverse Reaction: Diarrhea

Drug (Amoxicillin)

Comparator (Penicillin VK)

Population

Dose

Dosage Form

Indication

Number of Patients (Amoxicillin)

Number of Patients (Penicillin VK)

2%

2%

Adolescents and adults

775 mg daily for 10 days

Extended-release tablets

Tonsillitis and/or pharyngitis

302

306

Amoxicillin: Adverse Reaction: Nausea

Drug (Amoxicillin)

Comparator (Penicillin VK)

Population

Dose

Dosage Form

Indication

Number of Patients (Amoxicillin)

Number of Patients (Penicillin VK)

1%

0.7%

Adolescents and adults

775 mg daily for 10 days

Extended-release tablets

Tonsillitis and/or pharyngitis

302

306

Genitourinary: Vulvovaginal infection (2%)

Nervous system: Headache (1%)

<1%: Gastrointestinal: Abdominal pain, vomiting (table 3)

Amoxicillin: Adverse Reaction: Vomiting

Drug (Amoxicillin)

Comparator (Penicillin VK)

Population

Dose

Dosage Form

Indication

Number of Patients (Amoxicillin)

Number of Patients (Penicillin VK)

0.7%

2%

Adolescents and adults

775 mg daily for 10 days

Extended-release tablets

Tonsillitis and/or pharyngitis

302

306

Postmarketing:

Cardiovascular: Hypersensitivity angiitis (Garcia-Porrua 1999)

Dermatologic: Acute generalized exanthematous pustulosis (Choon 2018), erythema multiforme, erythematous maculopapular rash (Koosakulchai 2021), exfoliative dermatitis, skin rash (Katoh 2021), Stevens-Johnson syndrome (Yang 2020), toxic epidermal necrolysis (Yang 2020), urticaria (Koosakulchai 2021)

Gastrointestinal: Clostridioides difficile associated diarrhea, Clostridioides difficile colitis, hemorrhagic colitis, melanoglossia, mucocutaneous candidiasis, staining of tooth

Genitourinary: Crystalluria

Hematologic & oncologic: Agranulocytosis, anemia, eosinophilia, hemolytic anemia (Rossi 2010), immune thrombocytopenia, leukopenia, neutropenia (Curtis 2017), thrombocytopenia

Hepatic: Cholestatic hepatitis (Kim 2011), cholestatic jaundice, hepatitis (acute cytolytic), increased serum alanine aminotransferase (Kim 2011), increased serum aspartate aminotransferase (Kim 2011)

Hypersensitivity: Anaphylaxis (Piotin 2021), angioedema (Koosakulchai 2021)

Immunologic: Drug reaction with eosinophilia and systemic symptoms (De La Cruz 2021), serum sickness-like reaction (Mohsenzadeh 2020)

Nervous system: Agitation, anxiety, behavioral changes, confusion, dizziness, hyperactive behavior (reversible), insomnia, seizure

Contraindications

Serious hypersensitivity to amoxicillin (eg, anaphylaxis, Stevens-Johnson syndrome) or to other beta-lactams, or any component of the formulation

Canadian labeling: Additional contraindications (not in US labeling): Infectious mononucleosis (suspected or confirmed)

Warnings/Precautions

Concerns related to adverse effects:

• Superinfection: Prolonged use may result in fungal or bacterial superinfection.

Disease-related concerns:

• Infectious mononucleosis: A high percentage of patients with infectious mononucleosis develop an erythematous rash during amoxicillin therapy; avoid use in these patients.

• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

• Chewable tablets: May contain phenylalanine; see manufacturer's labeling.

Metabolism/Transport Effects

Substrate of OAT1/3

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Acemetacin: May increase the serum concentration of Penicillins. Risk C: Monitor therapy

Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin. Risk C: Monitor therapy

Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Risk C: Monitor therapy

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. Risk C: Monitor therapy

Immune Checkpoint Inhibitors: Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors. Risk C: Monitor therapy

Khat: May decrease the serum concentration of Amoxicillin. Management: Consider administering amoxicillin before, or 2 hours after, khat chewing to avoid reductions in amoxicillin bioavailability. Risk D: Consider therapy modification

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Methotrexate: Penicillins may increase the serum concentration of Methotrexate. Risk C: Monitor therapy

Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Penicillins. Risk C: Monitor therapy

Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Tetracyclines: May diminish the therapeutic effect of Penicillins. Risk C: Monitor therapy

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Pregnancy Considerations

Amoxicillin crosses the placenta (Muller 2009; Zareba-Szczudlik 2017). Maternal serum concentrations are significantly greater than the umbilical cord, placenta, and amniotic fluid concentrations when amoxicillin is administered orally prior to delivery (Buckingham 1975; Zareba-Szczudlik 2017).

Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of oral amoxicillin may be altered. Renal clearance is increased in the second and third trimester compared to postpartum values. In addition, oral absorption is decreased during labor. Maternal adipose tissue and the presence of anemia may influence maternal serum and amniotic fluid concentrations. Although minimum inhibitory concentrations can be reached, higher oral doses (or a parenteral antibiotic) may be needed based on the specific maternal infection or if treating an infection of the fetus and/or placenta (Andrew 2007; Buckingham 1975; Zareba-Szczudlik 2017).

As a class, penicillin antibiotics are widely used in pregnant patients. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).

Amoxicillin may be used for the management of Bacillus anthracis in pregnant patients when penicillin susceptibility is documented. Maternal infection with B. anthracis may cause preterm labor, fetal infection, fetal distress, or fetal loss. Maternal death may also occur. Amoxicillin is an alternative agent for the treatment of cutaneous anthrax without systemic involvement and for the postexposure prophylaxis of B. anthracis during pregnancy. The dose and duration of amoxicillin therapy in pregnant and postpartum patients is the same as in nonpregnant adults. Adjustments in dose for pregnancy are not recommended until additional pharmacokinetic data become available (Meaney-Delman 2014).

Untreated chlamydial disease can cause pelvic inflammatory disease, ectopic pregnancy, and infertility. In addition, treatment of maternal disease usually prevents transmission to the neonate during birth. Due to concerns of chlamydia persistence following exposure to penicillin class antibiotics, amoxicillin is an alternative antibiotic for the treatment of chlamydial infections in pregnancy (CDC [Workowski 2021]).

Amoxicillin is used for the treatment of Lyme disease. Vertical transmission from mother to fetus is not well documented; it is unclear if infection increases the risk of adverse pregnancy outcomes. When treatment for Lyme disease in pregnancy is needed, the indications and dosing of amoxicillin are the same as in nonpregnant patients (IDSA/AAN/ACR [Lantos 2021]; Lambert 2020; SOGC [Smith 2020]).

Untreated urinary tract infections (UTIs) during pregnancy are associated with an increased risk of developing pyelonephritis, low birth weight, and preterm labor. Amoxicillin may be an option for the treatment of UTI during pregnancy (de Rossi 2020; IDSA [Nicolle 2019]).

Amoxicillin is used in the management of H. pylori eradication. H. pylori is associated with hyperemesis gravidarum and may be linked to other adverse maternal and fetal outcomes. Treatment in patients with mild or no symptoms is generally delayed until after delivery; however, amoxicillin may be considered as part of a treatment regimen when otherwise appropriate (Cardaropoli 2014; Nguyen 2019; Zhan 2019).

Amoxicillin can also be used in the management of preterm prelabor rupture of membranes (PROM); treatment with antibiotics is used to prolong pregnancy and decrease maternal and newborn infections (ACOG 217 2020). Amoxicillin may also be used in certain situations prior to vaginal delivery in patients at high risk for endocarditis (ACOG 199 2018).

Amoxicillin is considered compatible for the treatment airway diseases in pregnant patients (ERS/TSANZ [Middleton 2020]).

Breastfeeding Considerations

Amoxicillin is present in breast milk (Kafetzis 1981).

Information related to the presence of amoxicillin in breast milk is available from 6 mothers given oral amoxicillin 1,000 mg on the third day postpartum. The mean peak maternal serum concentration (15.6 mcg/mL) occurred at 2 hours after the dose. The mean peak milk concentration occurred 4 to 5 hours after the dose and was 0.9 mcg/mL (range: 0.68 to 1.3 mcg/mL) (Kafetzis 1981).

Self-limiting diarrhea, rash, and somnolence have been reported in nursing infants exposed to amoxicillin (Benyamini 2005; Goldstein 2009; Ito 1993); the manufacturer warns of the potential for allergic sensitization in the infant. In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).

Although the manufacturer recommends that caution be exercised when administering amoxicillin to breastfeeding patients, amoxicillin is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002).

Amoxicillin may be used to treat mastitis in breastfeeding patients. The treatment of mastitis with antibiotics is generally not considered unless symptoms do not improve with conservative management or the patient is acutely ill. When antibiotics are clinically indicated for treatment, amoxicillin is one of the suggested therapies for gram-negative organisms (WHO 2000).

Recommendations for using amoxicillin for the treatment of B. anthracis in breastfeeding patients are the same as in pregnancy. Exposure to anthrax is not considered a contraindication to breastfeeding. However, if there are active cutaneous lesions on the breast, contact with the infant should be avoided and feeding from the affected breast should not occur until >48 hours of appropriate antibiotic therapy (Meaney-Delman 2014).

Dietary Considerations

Some products may contain phenylalanine.

Monitoring Parameters

With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; assess patient at beginning and throughout therapy for infection; monitor for signs of anaphylaxis during first dose

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacokinetics

Absorption: Oral:

Immediate release: Rapid with or without food; delayed absorption may be seen in some neonates and infants <60 days of age (Mir 2020).

Extended release: Rate of absorption is slower compared to immediate-release formulations; food decreases the rate but not extent of absorption.

Distribution: Readily into liver, lungs, prostate, muscle, middle ear effusions, maxillary sinus secretions, bone, gallbladder, bile, and ascitic and synovial fluids; poor cerebrospinal fluid penetration (except when meninges are inflamed).

Vd:

Neonates, including preterm (GA: 25 to 42 weeks; PNA: ≤9 days): 0.65 ± 0.13 L/kg (Pullen 2006).

Infants ≥3 months of age and children ≤5 years of age: 1.44 ± 0.37 L/kg (Canafax 1998).

Protein binding: ~20%.

Bioavailability: Oral suspension: Neonates (GA: 37 to 43 weeks; PNA: 6 to 12 days): 75% (range: 60% to 101%) (Lönnerholm 1982).

Half-life elimination:

Preterm and term neonates (GA: 25 to 42 weeks; PNA: ≤9 days): Immediate release: 5.2 ± 1.9 hours (Pullen 2006).

Adults: Immediate release: 61.3 minutes; extended release: 90 minutes.

Time to peak:

Preterm and term neonates (PNA: <5 days): Oral suspension: ~4 hours (Cohen 1975; Weingartner 1977); reported mean range: 2 to 6 hours (Keij 2019).

Adults: Capsule, oral suspension: 1 to 2 hours; chewable tablet: 1 hour; extended release: 3.1 hours.

Excretion: Urine (60% as unchanged drug); lower in neonates (Cohen 1975; Weingartner 1977).

Pharmacokinetics: Additional Considerations

Anti-infective considerations:

Parameters associated with efficacy:

Time dependent; associated with time free drug concentration (fT) > minimum inhibitory concentration, goal: ≥40% to 50% (bactericidal) (Andes 1998; Craig 1996; Craig 1998; Gustafsson 2001).

Expected drug exposure in normal renal function:

Infants ≥3 months of age and children ≤4 years of age, Cmax (peak):

15 mg/kg/dose 3 times daily, steady state: 7.9 ± 3.5 mg/L (Fonseca 2003).

25 mg/kg/dose twice daily, steady state: 10.6 ± 5.1 mg/L (Fonseca 2003).

Adults, Cmax (peak):

125 mg, single dose (125 mg per 5 mL suspension): 1.5 to 3 mg/L.

250 mg, single dose (capsule or 250 mg per 5 mL suspension): 3.5 to 5 mg/L.

400 mg, single dose (chewable tablet): 5.18 ± 1.64 mg/L.

400 mg, single dose (400 mg per 5 mL suspension): 5.92 ± 1.62 mg/L.

500 mg, single dose: 5.5 to 7.5 mg/L.

875 mg, single dose: 13.8 ± 4.1 mg/L.

Postantibiotic effect:

H. influenzae: <1 hour; S. pneumoniae: 0.3 to 5.8 hours; viridans streptococci: 0.7 to 2 hours (Davies 2000; Dubois 2000; Lee 2000).

Pricing: US

Capsules (Amoxicillin Oral)

250 mg (per each): $0.13 - $0.25

500 mg (per each): $0.19 - $0.39

Chewable (Amoxicillin Oral)

125 mg (per each): $0.37

250 mg (per each): $0.74

Suspension (reconstituted) (Amoxicillin Oral)

125 mg/5 mL (per mL): $0.04

200 mg/5 mL (per mL): $0.09

250 mg/5 mL (per mL): $0.06

400 mg/5 mL (per mL): $0.10

Tablets (Amoxicillin Oral)

500 mg (per each): $0.50

875 mg (per each): $0.87

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • A.M. Mox (TH);
  • Abiolex (CL);
  • Acilina (PY);
  • Acimox (MX);
  • Adbiotin (CO);
  • Alemox (EG);
  • Alfamox (IT);
  • Almacin (HR);
  • Almorsan (AR);
  • Alphamox (AU);
  • Amicil (MX);
  • Amimox (SE);
  • Amitron (ES);
  • Amixen (AR);
  • Amixozan (DK);
  • Ammimox (TH);
  • Amobay (MX);
  • Amobiotic (CL);
  • Amoclan (JO, SA);
  • Amodex (FR);
  • Amoksilav (TR);
  • Amolin (JP, TW);
  • Amorion (FI);
  • Amosin (RU);
  • Amotaks (PL);
  • Amoval (PE, PY);
  • Amox (IT);
  • Amoxa (SG);
  • Amoxal (CO, VE);
  • Amoxapen (ET, HK, MT);
  • Amoxar (DK);
  • Amoxcillin (TH);
  • Amoxcin (TW);
  • Amoxen (ZW);
  • Amoxi-SAAR (DE);
  • Amoxibay (CO);
  • Amoxibel (JO);
  • Amoxibeta (DE);
  • Amoxicap (HK, PK, ZA);
  • Amoxicid (EG);
  • Amoxicilina (CO, EC);
  • Amoxiclin (PE);
  • Amoxidal (AR, UY);
  • Amoxidin (AE);
  • Amoxidin 7 (PE);
  • Amoxidrex (LB);
  • Amoxifur (MX);
  • Amoxiga (CO, VE);
  • Amoxigran (HK);
  • Amoxil (AE, AU, BH, BR, EC, EG, ET, GB, GR, ID, IE, JO, KW, LT, MT, MX, NZ, PE, PT, QA, SA, UA, ZA);
  • Amoxilan (AT, VE);
  • Amoxilin (CN);
  • Amoximex (LB);
  • Amoxin (FI, IS);
  • Amoxipen (AE, PE, VN);
  • Amoxipenil (CL);
  • Amoxisol (MX);
  • Amoxistad (AT);
  • Amoxitab (HK);
  • Amoxivan (IN);
  • Amoxivet (MX);
  • Amoxsan (ID);
  • Amoxy (CN);
  • Amoxy Care Forte (IL);
  • Amoxydar (AE, JO, QA, SA);
  • Ampin (PK);
  • Amyn (LK);
  • Anamox (PY);
  • Apimox (BD);
  • Aproxal (GR, JO);
  • Aramox (EG);
  • Aroxin (SG);
  • Atak (BR);
  • Atoksilin (TR);
  • Avlomox (BD);
  • Bactox (LV);
  • Bactox Ge (FR);
  • Balmox (ZW);
  • Beamoxy (MY);
  • Berlimox (ID);
  • Betamox (MY);
  • Betmox (IN);
  • Brumox (PH);
  • Bufamoxy (ID);
  • Cilamox (AU);
  • Cipamox (PK, PT);
  • Clamoxyl (BE, CH, ES, FR, LU, PT);
  • Clonamox (HU, IE);
  • Coamox (TH);
  • Danoxilin (ID);
  • Devamox (TR);
  • Dimopen (MX);
  • Duomox (BG, CZ, HU, PL, RO);
  • Duzimicin (BR);
  • Dymoxin (TH);
  • E-Mox (AE, ET, QA, SA);
  • Ecobol (RU);
  • Edamox (HK);
  • Elmox (PK);
  • Ethimox (ID);
  • Fabamox (PY, UY);
  • Fisamox (AU);
  • Flemoxin (AE, BE, DK, KW, PT, QA, RU, UA);
  • Foxolin (KR);
  • Gemox (TW);
  • Geramox (IE);
  • Gexcil (PH);
  • Gimalxina (MX);
  • Glomox (AE, LB, QA, SA);
  • Gramox (RU, UA);
  • Grinsul (AR);
  • Grunamox (EC);
  • Hiconcil (LT, LV, PL, VN);
  • Hikoncil (UA);
  • Hymox (AE, JO, KW, QA, SA);
  • Hypher (CN);
  • Ibiamox (NZ, TH);
  • Ikamoxyl (ID);
  • Imacillin (DK, NO, SE);
  • Imadrax (DK);
  • Imox (ET, ZW);
  • InfectoMox (DE);
  • J Mox (BD);
  • Julphamox (AE, JO, KW, LB, QA, SA);
  • Jutamox (DE);
  • Kemox (IN);
  • Kymoxin (KR);
  • Lamoxy (IN);
  • Largopen (ET);
  • Linmox (VE);
  • Loxyl (BD);
  • Magnimox (PE);
  • Manmox (TH);
  • Max (IN);
  • Maxamox (AU);
  • Medomox (ZW);
  • Meixil (TH);
  • Mexylin (ID);
  • Miloxy (ZW);
  • Mopen (IT);
  • Morgenxil (ES);
  • Mox (IN);
  • Moxatid (BD);
  • Moxi (LK);
  • Moxicor (LK);
  • Moxifar (UY);
  • Moxilen (HK, JO, LB, LV, MT, MY, RO, SG, VN);
  • Moxilin (BD);
  • Moxiram (JO);
  • Moxol (LK);
  • Moxtam (UY);
  • Moxxo (TH);
  • Moxylin (EC);
  • Moxypen (IL, ZA);
  • Moxyvit (IL);
  • Mymox (LV);
  • Neomox (AE, BH, KW, SA);
  • Nobactam (AR);
  • Novamox (CL);
  • Novamoxin (KW);
  • Novax (ID);
  • Numoxylin (LK);
  • Ocylin (BR);
  • Opimox (ID);
  • Opimox Forte (ID);
  • Optamox (CL);
  • Oramox (IE);
  • Ospamox (AE, AT, BG, BH, CZ, EE, HR, HU, ID, JO, KW, LB, LT, LV, MY, NZ, PL, PT, QA, RU, SA, SI, SK, UA, VE);
  • Pamocil (IT, MT);
  • Pamoxin (KR);
  • Pasetocin (JP);
  • Penamox (AE, BH, ET, JO, KW, LB, QA, SA);
  • Pinamox (IE);
  • Pondnoxcill (TH);
  • Pyramox (TH);
  • Ranmoxy (AU, NZ, ZA);
  • Ranoxyl (AE, TH, ZW);
  • Remox (SA);
  • Remoxil (TR);
  • Ri Ao (CN);
  • Rivamox (ET);
  • Sanet (PY);
  • Sapox (BD);
  • Sawacillin (JP);
  • Sia-mox (TH);
  • Sinot (UY);
  • Sintopen (IT);
  • Solpenox (ID);
  • Strimox (SG, ZW);
  • Taimox (PH);
  • Telmox (AR);
  • Teramoxyl (PH);
  • Trifamox (AR);
  • Trimoxal (VE);
  • Ultramox (JO, KW);
  • Unimox (SG);
  • Velamox (BR, PE);
  • Widecillin (ID, JP);
  • Winpen (LV);
  • Yomax (ZA);
  • Zai Lin (CN);
  • Zeemox (PK);
  • Zerrsox (PH);
  • Zimox (IT);
  • Zymoxyl (PH)


For country code abbreviations (show table)
  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. Ahluwalia J, Abuabara K, Perman MJ, Yan AC. Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome. Br J Dermatol. 2015;172(4):1090-1095. doi:10.1111/bjd.13512 [PubMed 25369238]
  3. Ailes EC, Gilboa SM, Gill SK, et al. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. Birth Defects Res A Clin Mol Teratol. 2016;106(11):940-949. doi:10.1002/bdra.23570 [PubMed 27891788]
  4. Alarcón E, Sansosti A, Navarro B, et al. Amoxicillin-induced aseptic meningitis: 2 case reports and appraisal of the literature. J Investig Allergol Clin Immunol. 2019;29(3):248-250. doi:10.18176/jiaci.0380 [PubMed 31219042]
  5. American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.
  6. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
  7. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Prelabor rupture of membranes: ACOG Practice Bulletin, Number 217. Obstet Gynecol. 2020;135(3):e80-e97. doi:10.1097/AOG.0000000000003700 [PubMed 32080050]
  8. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 199: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2018;132(3):e103-e119. [PubMed 30134425]
  9. American College of Obstetricians and Gynecologists (ACOG). Prevention of group B streptococcal early-onset disease in newborns: ACOG Committee Opinion, Number 797. Obstet Gynecol. 2020;135(2):e51-e72. doi:10.1097/AOG.0000000000003668 [PubMed 31977795]
  10. American Dental Association (ADA); American Academy of Orthopedic Surgeons (AAOS). Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc. 2003;134(7):895-899. [PubMed 12892448]
  11. Amoxicillin [prescribing information]. North Wales, PA: Teva Pharmaceuticals; August 2018.
  12. Amoxicillin [prescribing information]. North Wales, PA: Teva Pharmaceuticals; January 2016.
  13. Amoxicillin [prescribing information]. Princeton, NJ: Neopharma Inc; September 2019.
  14. Amoxil (amoxicillin) [prescribing information]. Bristol, TN: Dr Reddy’s Laboratories; December 2015.
  15. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  16. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother. 1998;42(9):2375-2379. doi:10.1128/AAC.42.9.2375 [PubMed 9736566]
  17. Andrew MA, Easterling TR, Carr DB, et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther. 2007;81(4):547-556. [PubMed 17329990]
  18. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007:61, 153.
  19. Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. Circulation. 2015;132(15):1487-1515. [PubMed 26373317]
  20. Barker AF. Treatment of bronchiectasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 8, 2020.
  21. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346(5):334-339. doi:10.1056/NEJMcp011603 [PubMed 11821511]
  22. Belarmino JM and Kogan BA. Management of neonatal hydronephrosis. Early Hum Dev. 2006;82(1):9-14. [PubMed 16427220]
  23. Ben Fredj N, Aouam K, Chaabane A, et al. Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization. Br J Clin Pharmacol. 2010;70(2):273-276. doi:10.1111/j.1365-2125.2010.03685.x [PubMed 20653681]
  24. Benyamini L, Merlob P, Stahl B, et al, "The Safety of Amoxicillin/Clavulanic Acid and Cefuroxime During Lactation," Ther Drug Monit, 2005, 27(4):499-502. [PubMed 16044108]
  25. Berbari E, Baddour LM. Prosthetic joint infection: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. May 16, 2022.
  26. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9 [PubMed 30558872]
  27. Boguniewicz M and Leung DY, “Hypersensitivity Reactions to Antibiotics Commonly Used in Children,” Pediatr Infect Dis J, 1995, 14(3):221-31. [PubMed 7761188]
  28. Bonnefond S, Catroux M, Melenotte C, et al. Clinical features of actinomycosis: a retrospective, multicenter study of 28 cases of miscellaneous presentations. Medicine (Baltimore). 2016;95(24):e3923. doi:10.1097/MD.0000000000003923 [PubMed 27311002]
  29. Bontems P, Kalach N, Oderda G, et al. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53(6):646-650. doi:10.1097/MPG.0b013e318229c769 [PubMed 21701406]
  30. Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052-1062. doi:10.1002/phar.1649 [PubMed 26598097]
  31. Borges I, Faveri M, Figueiredo LC, et al. Different antibiotic protocols in the treatment of severe chronic periodontitis: a 1-year randomized trial. J Clin Periodontol. 2017;44(8):822-832. doi:10.1111/jcpe.12721 [PubMed 28303587]
  32. Bower WA, Schiffer J, Atmar RL, et al; CDC ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1 [PubMed 31834290]
  33. Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, Clin Infect Dis, 2011, 53(7):e25-76. [PubMed 21880587]
  34. Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J. 2010;29(11):1043-1046. doi:10.1097/INF.0b013e3181f42a53 [PubMed 20975453]
  35. Bradley JS, Nelson JD, Kimberlin DK, et al, eds. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 28th ed. American Academy of Pediatrics; 2022.
  36. Bradley JS, Peacock G, Krug SE, et al; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. Pediatrics. 2014;133(5):e1411-e1436. doi:10.1542/peds.2014-0563 [PubMed 24777226]
  37. Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6 [PubMed 26120552]
  38. Brook I. Treatment of actinomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 3, 2020.
  39. Brown KA, Fisman DN, Moineddin R, Daneman N. The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort study. PLoS One. 2014;9(8):e105454. doi:10.1371/journal.pone.0105454 [PubMed 25157757]
  40. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12 [PubMed 23478961]
  41. Brown KA, Langford B, Schwartz KL, Diong C, Garber G, Daneman N. Antibiotic prescribing choices and their comparative C. difficile infection risks: a longitudinal case-cohort study. Clin Infect Dis. 2021;72(5):836-844. doi:10.1093/cid/ciaa124 [PubMed 32069358]
  42. Buckingham M, Welply G, Miller JF, Elstein M. Gastro-intestinal absorption and transplacental transfer of amoxycillin during labour and the influence of metoclopramide. Curr Med Res Opin. 1975;3(6):392-396. doi:10.1185/03007997509114794 [PubMed 1183221]
  43. Buonomo A, Nucera E, Pecora V, et al. Cross-reactivity and tolerability of cephalosporins in patients with cell-mediated allergy to penicillins. J Investig Allergol Clin Immunol. 2014;24(5):331-337. [PubMed 25345303]
  44. Butenko T, Jeverica S, Orel R, Homan M. Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children. Helicobacter. 2017;22(5):e12400. doi:10.1111/hel.12400 [PubMed 28653787]
  45. Canafax DM, Yuan Z, Chonmaitree T, Deka K, Russlie HQ, Giebink GS. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media. Pediatr Infect Dis J. 1998;17(2):149-156. doi:10.1097/00006454-199802000-00014 [PubMed 9493813]
  46. Cardaropoli S, Rolfo A, Todros T. Helicobacter pylori and pregnancy-related disorders. World J Gastroenterol. 2014;20(3):654-664. doi:10.3748/wjg.v20.i3.654 [PubMed 24574739]
  47. Caruso C, Valluzzi RL, Colantuono S, Gaeta F, Romano A. β-lactam allergy and cross-reactivity: a clinician's guide to selecting an alternative antibiotic. J Asthma Allergy. 2021;14:31-46. doi:10.2147/JAA.S242061 [PubMed 33500632]
  48. CDC and Johns Hopkins Working Group on Civilian Biodefense. Commentary on Non-Labeled Dosing of Oral Amoxicillin in Adults and Pediatrics for Post-Exposure Inhalational Anthrax. December 10, 2001. http://www.fda.gov/cder/drugprepare/amox-anthrax.htm
  49. Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  50. Centers for Disease Control and Prevention (CDC). FAQs for clinicians about C. diff. https://www.cdc.gov/cdiff/clinicians/faq.html. Updated March 27, 2020. Accessed July 27, 2021 [PubMed CDC.1]
  51. Chew C, Goenka A. QUESTION 2: Does amoxicillin exposure increase the risk of rash in children with acute Epstein-Barr virus infection? Arch Dis Child. 2016;101(5):500-502. doi:10.1136/archdischild-2015-310364 [PubMed 26893522]
  52. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection [published correction appears in Am J Gastroenterol. 2018;113(7):1102]. Am J Gastroenterol. 2017;112(2):212-239. doi:10.1038/ajg.2016.563 [PubMed 28071659]
  53. Cho CB. Adverse reactions to drugs. In: Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Elsevier; 2020:chap. 177. [PubMed cho.2020]
  54. Choon SE, Der YS, Lai NLJ, Yu SEE, Yap XL, Nalini NM. Clinical characteristics, culprit drugs and outcome of patients with Acute Generalised Exanthematous Pustulosis seen in Hospital Sultanah Aminah, Johor Bahru. Med J Malaysia. 2018;73(4):220-225. [PubMed 30121684]
  55. Chovel-Sella A, Ben Tov A, Lahav E, et al. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics. 2013;131(5):e1424-e1427. doi:10.1542/peds.2012-1575 [PubMed 23589810]
  56. Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72-e112. [PubMed 22438350]
  57. Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 9, 2022.
  58. Christian-Kopp S, Sinha M, Rosenberg DI, Eisenhart AW, McDonald FW. Antibiotic dosing for acute otitis media in children: a weighty issue. Pediatr Emerg Care. 2010;26(1):19-25. doi:10.1097/PEC.0b013e3181cbeb00 [PubMed 20042912]
  59. Cohen MD, Raeburn JA, Devine J, et al. Pharmacology of some oral penicillins in the newborn infant. Arch Dis Child. 1975;50(3):230-234. doi:10.1136/adc.50.3.230 [PubMed 1147656]
  60. Coignard-Biehler H, Lanternier F, Hot A, et al. Adherence to preventive measures after splenectomy in the hospital setting and in the community. J Infect Public Health. 2011;4(4):187-194. doi:10.1016/j.jiph.2011.06.004 [PubMed 22000846]
  61. Cole KA, Kenney RM, Perri MB, et al. Outcomes of aminopenicillin therapy for vancomycin-resistant enterococcal urinary tract infections. Antimicrob Agents Chemother. 2015;59(12):7362-7366. [PubMed 26369973]
  62. Connelly S, Subramanian P, Hasan NA, Colwell RR, Kaleko M. Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome. Anaerobe. 2018;53:82-93. doi:10.1016/j.anaerobe.2018.04.012 [PubMed 29689301]
  63. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10. doi:10.1086/516284 [PubMed 9455502]
  64. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015 [PubMed 8852915]
  65. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188 [PubMed 19884587]
  66. Crowe SE. Treatment regimens for Helicobacter pylori. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 5, 2020.
  67. Currie DC, Garbett ND, Chan KL, et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med. 1990;76(280):799-816. [PubMed 2217684]
  68. Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program. 2017;2017(1):187-193. doi:10.1182/asheducation-2017.1.187 [PubMed 29222255]
  69. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050 [PubMed 31260651]
  70. Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE. Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of augmentin. Br J Clin Pharmacol. 1988;26(4):385-390. doi:10.1111/j.1365-2125.1988.tb03395.x [PubMed 3190988]
  71. Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother. 2000;44(2):304-310. doi:10.1128/aac.44.2.304-310.2000 [PubMed 10639354]
  72. De La Cruz AC, Ashraf S, Shrestha N, Saad M. Myocarditis and drug rash with eosinophilia and systemic symptoms syndrome: a deadly combination. Cureus. 2021;13(2):e13496. doi:10.7759/cureus.13496 [PubMed 33777581]
  73. de Rossi P, Cimerman S, Truzzi JC, et al. Joint report of SBI (Brazilian Society of Infectious Diseases), FEBRASGO (Brazilian Federation of Gynecology and Obstetrics Associations), SBU (Brazilian Society of Urology) and SBPC/ML (Brazilian Society of Clinical Pathology/Laboratory Medicine): recommendations for the clinical management of lower urinary tract infections in pregnant and non-pregnant women. Braz J Infect Dis. 2020;24(2):110-119. doi:10.1016/j.bjid.2020.04.002 [PubMed 32360431]
  74. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129 [PubMed 23620467]
  75. Dibek Misirlioglu E, Guvenir H, Ozkaya Parlakay A, et al. Incidence of antibiotic-related rash in children with Epstein-Barr virus infection and evaluation of the frequency of confirmed antibiotic hypersensitivity. Int Arch Allergy Immunol. 2018;176(1):33-38. doi:10.1159/000481988 [PubMed 29617685]
  76. Di Lernia V, Mansouri Y. Epstein-Barr virus and skin manifestations in childhood. Int J Dermatol. 2013;52(10):1177-1184. doi:10.1111/j.1365-4632.2012.05855.x [PubMed 24073903]
  77. Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. Cloherty and Stark's Manual of Neonatal Care. 8th edition. Lippincott Williams & Wilkins; 2017.
  78. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999;18(1):1-9. [PubMed 9951971]
  79. Dubois J, St-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. Diagn Microbiol Infect Dis. 2000;37(3):187-193. doi:10.1016/s0732-8893(00)00141-3 [PubMed 10904192]
  80. Exius R, Gabrielli S, Abrams EM, et al. Establishing Amoxicillin Allergy in Children Through Direct Graded Oral Challenge (GOC): Evaluating Risk Factors for Positive Challenges, Safety, and Risk of Cross-Reactivity to Cephalosporines. J Allergy Clin Immunol Pract. Published online July 19, 2021. doi:10.1016/j.jaip.2021.06.057 [PubMed 34293504]
  81. Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP. Pharmacodynamic target attainment of oral beta-lactams for the empiric treatment of acute otitis media in children. Paediatr Drugs. 2008;10(5):329-335. doi:10.2165/00148581-200810050-00006 [PubMed 18754699]
  82. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51-69.e14. [PubMed 27102658]
  83. File TM. Treatment of community-acquired pneumonia in adults in the outpatient setting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 7, 2020.
  84. File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 28, 2021
  85. Finegold SM, Gentry LO, Mogabgab W, Campbell SC, Skatrud J. Controlled comparative trial of bacampicillin and amoxicillin in therapy of bacterial infections of the lower respiratory tract. Rev Infect Dis. 1981;3(1):150-153. [PubMed 7012996]
  86. Fonseca W, Hoppu K, Rey LC, Amaral J, Qazi S. Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. Antimicrob Agents Chemother. 2003;47(3):997-1001. doi:10.1128/aac.47.3.997-1001.2003 [PubMed 12604533]
  87. Francke EL, Appel GB, Neu HC. Kinetics of intravenous amoxicillin in patients on long-term dialysis. Clin Pharmacol Ther. 1979;26(1):31-35. doi:10.1002/cpt197926131 [PubMed 445959]
  88. Garbutt J, St Geme JW 3rd, May A, Storch GA, Shackelford PG. Developing community-specific recommendations for first-line treatment of acute otitis media: is high-dose amoxicillin necessary? Pediatrics. 2004;114(2):342-347. doi:10.1542/peds.114.2.342 [PubMed 15286214]
  89. Garbutt JM, Banister C, Spitznagel E, Piccirillo JF. Amoxicillin for acute rhinosinusitis: a randomized controlled trial. JAMA. 2012;307(7):685-692. [PubMed 22337680]
  90. García-Porrúa C, González-Gay MA, López-Lázaro L. Drug associated cutaneous vasculitis in adults in northwestern Spain. J Rheumatol. 1999;26(9):1942-1944. [PubMed 10493674]
  91. Garrison GD, Sorum PC, Hioe W, Miller MM. High-dose versus standard-dose amoxicillin for acute otitis media. Ann Pharmacother. 2004;38(1):15-19. doi:10.1345/aph.1D052 [PubMed 14742786]
  92. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009;119(11):1541-1551. doi:10.1161/CIRCULATIONAHA.109.191959 [PubMed 19246689]
  93. Gillies M, Ranakusuma A, Hoffmann T, et al. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. CMAJ. 2015;187(1):E21-E31. doi:10.1503/cmaj.140848 [PubMed 25404399]
  94. Girelli F, Bernardi S, Gardelli L, et al. A new case of DRESS syndrome induced by sulfasalazine and triggered by amoxicillin. Case Rep Rheumatol. 2013;2013:409152. doi:10.1155/2013/409152 [PubMed 23936716]
  95. Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M. The safety of macrolides during lactation. Breastfeed Med. 2009;4(4):197-200. [PubMed 19366316]
  96. Golightly LK, Teitelbaum I, Kiser TH, et al, eds. Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys. New York, NY: Springer Science; 2013.
  97. Green SM, Rothrock SG. Single-dose intramuscular ceftriaxone for acute otitis media in children. Pediatrics. 1993;91(1):23-30. [PubMed 8416502]
  98. Greenbaum LA and Mesrobian HG. Vesicoureteral reflux. Pediatr Clin North Am. 2006;53(3):413-427. [PubMed 16716788]
  99. Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 16, 2021b.
  100. Gupta K. Urinary tract infections and asymptomatic bacteriuria in pregnancy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 11, 2021a.
  101. Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257 [PubMed 21292654]
  102. Gustafsson I, Löwdin E, Odenholt I, Cars O. Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrob Agents Chemother. 2001;45(9):2436-2440. doi:10.1128/aac.45.9.2436-2440.2001 [PubMed 11502511]
  103. Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007;69(1):91-102. [PubMed 17522387]
  104. Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434. [PubMed 26785402]
  105. Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2). doi:10.3201/eid2002.130687 [PubMed 24447897]
  106. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742-748. doi:10.1093/jac/dkr508 [PubMed 22146873]
  107. Hoberman A, Paradise JL, Rockette HE, et al. Shortened antimicrobial treatment for acute otitis media in young children. N Engl J Med. 2016;375(25):2446-2456. doi:10.1056/NEJMoa1606043 [PubMed 28002709]
  108. Homme JH. Acute otitis media and group A streptococcal pharyngitis: a review for the general pediatric practitioner. Pediatr Ann. 2019;48(9):e343-e348. doi:10.3928/19382359-20190813-01 [PubMed 31505007]
  109. Hsu K. Treatment of Chlamydia trachomatis infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 10, 2022.
  110. Hu L. Treatment of Lyme disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 29, 2021.
  111. Hum SW, Shaikh KJ, Musa SS, Shaikh N. Adverse events of antibiotics used to treat acute otitis media in children: a systematic meta-analysis. J Pediatr. 2019;215:139-143.e7. [PubMed 31561959]
  112. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  113. Isla A, Trocóniz IF, Canut A, et al. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain. Enferm Infecc Microbiol Clin. 2011;29(3):167-173. doi:10.1016/j.eimc.2010.05.008 [PubMed 21334779]
  114. Ito S, Blajchman A, Stephenson M, et al. Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication. Am J Obstet Gynecol. 1993;168(5):1393-1399. [PubMed 8498418]
  115. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  116. Iwańczak BM, Borys-Iwanicka A, Biernat M, Gościniak G. Assessment of sequential and standard triple therapy in treatment of Helicobacter pylori infection in children dependent on bacteria sensitivity to antibiotics. Adv Clin Exp Med. 2016;25(4):701-708. doi:10.17219/acem/38554 [PubMed 27629844]
  117. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol. 2001;184(7):1352-1354. doi:10.1067/mob.2001.115050 [PubMed 11408852]
  118. Jevsevar DS, Abt E. The New AAOS-ADA Clinical Practice Guideline on Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures. J Am Acad Orthop Surg. 2013;21(3):195-197. [PubMed 23457071]
  119. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;64(6):991-1003. doi:10.1097/MPG.0000000000001594 [PubMed 28541262]
  120. Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand. 1981;70(3):285-288. [PubMed 7246123]
  121. Katoh Y, Natsume O, Matsunaga M, Takayanagi F, Uchida H, Yasuoka R. Diagnosis of non-immediate hypersensitivity to amoxicillin in children by skin test and drug provocation tests: a retrospective case-series study. Allergol Int. Published online August 9, 2021. doi:10.1016/j.alit.2021.07.009 [PubMed 34384710]
  122. Keij FM, Kornelisse RF, Hartwig NG, Reiss IKM, Allegaert K, Tramper-Stranders GA. Oral antibiotics for neonatal infections: a systematic review and meta-analysis. J Antimicrob Chemother. 2019;74(11):3150-3161. doi:10.1093/jac/dkz252 [PubMed 31236572]
  123. Keller F, Schröppel B, Ludwig U. Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction. World J Nephrol. 2015;4(3):330-344. doi:10.5527/wjn.v4.i3.330 [PubMed 26167456]
  124. Kim JS, Jang YR, Lee JW, et al. A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage. Korean J Hepatol. 2011;17(3):229-232. doi:10.3350/kjhep.2011.17.3.229 [PubMed 22102391]
  125. Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53(2):230-243. [PubMed 21558964]
  126. Koosakulchai V, Sangsupawanich P, Wantanaset D, Jessadapakorn W, Jongvilaikasem P, Yuenyongviwat A. Safety of direct oral provocation testing using the amoxicillin-2-step-challenge in children with history of non-immediate reactions to amoxicillin. World Allergy Organ J. 2021;14(7):100560. doi:10.1016/j.waojou.2021.100560 [PubMed 34306301]
  127. Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. Cochrane Database Syst Rev. 2010;2010(9):CD001095. doi:10.1002/14651858.CD001095.pub2 [PubMed 20824827]
  128. Kuehn J, Ismael Z, Long PF, Barker CI, Sharland M. Reported rates of diarrhea following oral penicillin therapy in pediatric clinical trials. J Pediatr Pharmacol Ther. 2015;20(2):90-104. doi:10.5863/1551-6776-20.2.90 [PubMed 25964726]
  129. Kutluk G, Tutar E, Bayrak A, et al. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?. Eur J Gastroenterol Hepatol. 2014;26(11):1202-1208. doi:10.1097/MEG.0000000000000190 [PubMed 25171023]
  130. Lambert JS. An overview of tickborne infections in pregnancy and outcomes in the newborn: the need for prospective studies. Front Med (Lausanne). 2020;7:72. doi:10.3389/fmed.2020.00072 [PubMed 32211414]
  131. Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580 [PubMed 25189188]
  132. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. Arthritis Care Res (Hoboken). 2021;73(1):1-9. doi:10.1002/acr.24495 [PubMed 33251700]
  133. Lee GM. Preventing infections in children and adults with asplenia. Hematology Am Soc Hematol Educ Program. 2020;2020(1):328-335. doi:10.1182/hematology.2020000117 [PubMed 33275684]
  134. Lee SY. Postantibiotic effects and postantibiotic sub-MIC effects of amoxicillin on streptococcus gordonii and streptococcus sanguis. J Chemother. 2000;12(5):379-384. doi:10.1179/joc.2000.12.5.379 [PubMed 11128556]
  135. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964-e999. doi:10.1542/peds.2012-3488 [PubMed 23439909]
  136. Limb CJ, Lustig LR, Durand ML. Acute otitis media in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 16, 2022.
  137. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernandez-Diaz S. Maternal exposure to amoxicillin and the risk of oral clefts. Epidemiology. 2012;23(5):699-705. [PubMed 22766750]
  138. Lindbaek M, Hjortdahl P, Johnsen UL. Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. BMJ. 1996;313(7053):325-329. [PubMed 8760738]
  139. Litao G, Jingjing S, Yu L, Lei Z, Xiaona H, Zhijing Z. Risk factors for antibiotic-associated diarrhea in critically ill patients. Med Sci Monit. 2018;24:5000-5007. doi:10.12659/MSM.911308 [PubMed 30020891]
  140. Lockhart PB, Tampi MP, Abt E, et al. Evidence-based clinical practice guideline on antibiotic use for the urgent management of pulpal- and periapical-related dental pain and intraoral swelling: A report from the American Dental Association. J Am Dent Assoc. 2019;150(11):906-921.e12. doi:10.1016/j.adaj.2019.08.020 [PubMed 31668170]
  141. Lönnerholm G, Bengtsson S, Ewald U. Oral pivampicillin and amoxycillin in newborn infants. Scand J Infect Dis. 1982;14(2):127-130. doi:10.3109/inf.1982.14.issue-2.10 [PubMed 7100823]
  142. Lusk RH, Fekety FR Jr, Silva J Jr, et al. Gastrointestinal side effects of clindamycin and ampicillin therapy. J Infect Dis. 1977;135 suppl:S111-S119. doi:10.1093/infdis/135.supplement.s111 [PubMed 850084]
  143. Ma H, Zhang L, Zhang Y, Liu Y, He Y, Guo L. Combined administration of antibiotics increases the incidence of antibiotic-associated diarrhea in critically ill patients. Infect Drug Resist. 2019;12:1047-1054. doi:10.2147/IDR.S194715 [PubMed 31118710]
  144. Mandel EM, Kardatzke D, Bluestone CD, Rockette HE. A comparative evaluation of cefaclor and amoxicillin in the treatment of acute otitis media. Pediatr Infect Dis J. 1993;12(9):726-732. doi:10.1097/00006454-199309000-00005 [PubMed 8414799]
  145. Mantegazza C, Molinari P, D'Auria E, Sonnino M, Morelli L, Zuccotti GV. Probiotics and antibiotic-associated diarrhea in children: a review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Pharmacol Res. 2018;128:63-72. doi:10.1016/j.phrs.2017.08.001 [PubMed 28827186]
  146. Marchisio P, Galli L, Bortone B, et al. Updated guidelines for the management of acute otitis media in children by the Italian Society of Pediatrics: treatment. Pediatr Infect Dis J. 2019;38(12S suppl):S10-S21. doi:10.1097/INF.0000000000002452 [PubMed 31876601]
  147. Martin MV. The use of oral amoxycillin for the treatment of actinomycosis. A clinical and in vitro study. Br Dent J. 1984;156(7):252-254. [PubMed 6584159]
  148. Mattoo TK. Medical management of vesicoureteral reflux - quiz within the article. Don't overlook placebos. Pediatr Nephrol. 2007;22(8):1113-1120. [PubMed 17483966]
  149. McCormick DP, Chonmaitree T, Pittman C, et al. Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment. Pediatrics. 2005;115(6):1455-1465. doi:10.1542/peds.2004-1665 [PubMed 15930204]
  150. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085 [PubMed 29462280]
  151. McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol. 2016;22(11):3078-3104. doi:10.3748/wjg.v22.i11.3078 [PubMed 27003987]
  152. McIntosh K, "Community-Acquired Pneumonia in Children," N Engl J Med, 2002, 346(6):429-37. [PubMed 11832532]
  153. Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis. 2014;20(2). [PubMed 24457117]
  154. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Resp Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST [PubMed 31573350]
  155. Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019 [PubMed 31699837]
  156. Mir F, Pearce RE, Baig-Ansari N, et al. Serum amoxicillin levels in young infants (0-59 days) with sepsis treated with oral amoxicillin. Arch Dis Child. 2020;105(12):1208-1214. doi:10.1136/archdischild-2019-317342 [PubMed 32404437]
  157. Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112(7):988-1013. doi:10.1038/ajg.2017.154 [PubMed 28631728]
  158. Moghimi M, Salentijn E, Debets-Ossenkop Y, Karagozoglu KH, Forouzanfar T. Treatment of cervicofacial actinomycosis: a report of 19 cases and review of literature. Med Oral Patol Oral Cir Bucal. 2013;18(4):e627-e632. [PubMed 23722146]
  159. Mohsenzadeh A, Movahedi M, Saatchi M, et al. Serum sickness-like reactions in Iranian children: a registry-based study in a referral center. Allergol Immunopathol (Madr). 2020;48(5):424-429. doi:10.1016/j.aller.2019.07.012 [PubMed 32653225]
  160. Moxatag (amoxicillin) [prescribing information]. Locust Valley, NY: Fera Pharmaceuticals LLC; June 2015.
  161. Moxatag (amoxicillin) [prescribing information]. Locust Valley, NY: Fera Pharmaceuticals LLC; May 2022.
  162. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364 [PubMed 28722171]
  163. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020 [PubMed 28461374]
  164. Muller AE, Oostvogel PM, DeJongh J, et al. Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera. Antimicrob Agents Chemother. 2009;53(4):1574-1580. [PubMed 19164154]
  165. Murray BE. Treatment of enterococcal infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 8, 2021.
  166. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta-lactam antibiotics. Arch Intern Med. 2001;161(21):2538-2544. doi:10.1001/archinte.161.21.2538 [PubMed 11718584]
  167. Nasiri MJ, Goudarzi M, Hajikhani B, Ghazi M, Goudarzi H, Pouriran R. Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: a systematic review and meta-analysis. Anaerobe. 2018;50:32-37. doi:10.1016/j.anaerobe.2018.01.011 [PubMed 29408016]
  168. National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed October 5, 2021. https://www.nice.org.uk/guidance/cg183
  169. National Institute for Health and Care Excellence (NICE). Otitis media (acute): antimicrobial prescribing. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng91. Published March 2018. Accessed November 3, 2022.
  170. Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in special patient populations. Pharmacotherapy. 2019;39(10):1012-1022. doi:10.1002/phar.2318 [PubMed 31400244]
  171. Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):1611-1615. doi:10.1093/cid/ciz021 [PubMed 31506700]
  172. Novamoxin (amoxicillin) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; March 2020.
  173. Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1-e25. [PubMed 23223583]
  174. Parry MF, “The Penicillins,” Med Clin North Am, 1987, 71(6):1093-112. [PubMed 3320613]
  175. Pasternack MS. Prevention of sepsis in the asplenic patient. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 8, 2020.
  176. Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 23, 2021.
  177. Paulo CO, Jordão S, Correia-Pinto J, Ferreira F, Neves I. Actinomycosis, a lurking threat: a report of 11 cases and literature review. Rev Soc Bras Med Trop. 2018;51(1):7-13. doi:10.1590/0037-8682-0215-2017 [PubMed 29513846]
  178. Pavlos R, White KD, Wanjalla C, Mallal SA, Phillips EJ. Severe delayed drug reactions: role of genetics and viral infections. Immunol Allergy Clin North Am. 2017;37(4):785-815. doi:10.1016/j.iac.2017.07.007 [PubMed 28965641]
  179. Peled N, Pitlik S, Samra Z, Kazakov A, Bloch Y, Bishara J. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol. 2007;28(4):377-381. doi:10.1086/513723 [PubMed 17385141]
  180. Piotin A, Godet J, Trubiano JA, et al. Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. Ann Allergy Asthma Immunol. Published online July 13, 2021. doi:10.1016/j.anai.2021.07.005 [PubMed 34271183]
  181. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):pii:1700629. doi:10.1183/13993003.00629-2017 [PubMed 28889110]
  182. Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of infections in children with asplenia or hyposplenia. Infect Dis Clin North Am. 2007;21(3):697-710. [PubMed 17826619]
  183. Prigogine T, Glupczynski Y, Carpiaux JP, Blogie M, Yourassowsky E, Schmerber JS. Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin. J Antimicrob Chemother. 1988;21(suppl B):131-136. [PubMed 3129390]
  184. Puhó EH, Szunyogh M, Métneki J, Czeizel AE. Drug treatment during pregnancy and isolated orofacial clefts in Hungary. Cleft Palate Craniofac J. 2007;44(2):194-202. [PubMed 17328645]
  185. Pukander JS, Jero JP, Kaprio EA, Sorri MJ. Clarithromycin vs. amoxicillin suspensions in the treatment of pediatric patients with acute otitis media. Pediatr Infect Dis J. 1993;12(12 suppl 3):S118-S121. doi:10.1097/00006454-199312003-00005 [PubMed 8295812]
  186. Pullen J, Stolk LM, Nieman FH, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther Drug Monit. 2006;28(2):226-231. doi:10.1097/01.ftd.0000198648.39751.11 [PubMed 16628135]
  187. Reboli AC. Erysipelothrix infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 10, 2020.
  188. Refer to manufacturer's labeling.
  189. Rodríguez-Martín S, Martín-Merino E, Lerma V, et al. Active surveillance of severe cutaneous adverse reactions: a case-population approach using a registry and a health care database. Pharmacoepidemiol Drug Saf. 2018;27(9):1042-1050. doi:10.1002/pds.4622 [PubMed 30051945]
  190. Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Caruso C, Quaratino D. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2016;138(1):179-186. doi:10.1016/j.jaci.2016.01.025 [PubMed 27016799]
  191. Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quaratino D, Gaeta F. Cross-reactivity and tolerability of cephalosporins in patients with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol Pract. 2018;6(5):1662-1672. doi:10.1016/j.jaip.2018.01.020 [PubMed 29408440]
  192. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2)(suppl):S1-S39. doi:10.1177/0194599815572097 [PubMed 25832968]
  193. Rossi F, Ruggiero S, Gallo M, Simeone G, Matarese SM, Nobili B. Amoxicillin-induced hemolytic anemia in a child with glucose 6-phosphate isomerase deficiency. Ann Pharmacother. 2010;44(7-8):1327-1329. doi:10.1345/aph.1P030 [PubMed 20516363]
  194. Salvadori MI, Price VE; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing and treating infections in children with asplenia or hyposplenia. Paediatr Child Health. 2014;19(5):271-278. [PubMed 24855431]
  195. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother. 1991;27(4):405-425. [PubMed 1856121]
  196. Scholz H, Noack R. Multicenter, randomized, double-blind comparison of erythromycin estolate versus amoxicillin for the treatment of acute otitis media in children. AOM Study Group. Eur J Clin Microbiol Infect Dis. 1998;17(7):470-478. doi:10.1007/BF01691129 [PubMed 9764549]
  197. Schrüfer P, Brockow K, Stoevesandt J, Trautmann A. Predominant patterns of β-lactam hypersensitivity in a single German Allergy Center: exanthem induced by aminopenicillins, anaphylaxis by cephalosporins. Allergy Asthma Clin Immunol. 2020;16(1):102. doi:10.1186/s13223-020-00488-0 [PubMed 33292467]
  198. Schwarzer A, Urruzuno P, Iwańczak B, et al. New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr. 2011;52(4):424-428. doi:10.1097/MPG.0b013e3181fc8c58 [PubMed 21407111]
  199. Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160(5):1831-1841. doi:10.1053/j.gastro.2020.11.059 [PubMed 33524402]
  200. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65(12):e45-e80. doi:10.1093/cid/cix669 [PubMed 29053792]
  201. Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2014;58(10):1496]. Clin Infect Dis. 2012;55(10):e86-e102. [PubMed 22965026]
  202. Silva-Senem MX, Heller D, Varela VM, Torres MC, Feres-Filho EJ, Colombo AP. Clinical and microbiological effects of systemic antimicrobials combined to an anti-infective mechanical debridement for the management of aggressive periodontitis: a 12-month randomized controlled trial. J Clin Periodontol. 2013;40(3):242-251. doi:10.1111/jcpe.12052 [PubMed 23297772]
  203. Siqueira MB, Saleh A, Klika AK, et al. Chronic suppression of periprosthetic joint infections with oral antibiotics increases infection-free survivorship. J Bone Joint Surg Am. 2015;97(15):1220-1232. doi:10.2106/JBJS.N.00999 [PubMed 26246256]
  204. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881-891. doi:10.1093/jac/dkt477 [PubMed 24324224]
  205. Smith GN, Moore KM, Hatchette TF, Nicholson J, Bowie W, Langley JM. Committee Opinion No. 399: Management of tick bites and Lyme disease during pregnancy. J Obstet Gynaecol Can. 2020;42(5):644-653. doi:10.1016/j.jogc.2020.01.001 [PubMed 32414479]
  206. Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2015;146(1):11-16. [PubMed 25569493]
  207. Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 17, 2022.
  208. Spoială EL, Stanciu GD, Bild V, Ababei DC, Gavrilovici C. From evidence to clinical guidelines in antibiotic treatment in acute otitis media in children. Antibiotics (Basel). 2021;10(1):52. doi:10.3390/antibiotics10010052 [PubMed 33419114]
  209. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444 [PubMed 24973422]
  210. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42-48. doi:10.1093/cid/cir301 [PubMed 21653301]
  211. Swaminathan S, Alangaden GJ. Treatment of resistant enterococcal urinary tract infections. Curr Infect Dis Rep. 2010;12(6):455-464. [PubMed 21308555]
  212. Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48(4):431-436. doi:10.1097/mpg.0b013e318182e716 [PubMed 19330931]
  213. Szeto CC, Li PK, Johnson DW, et al. ISPD Catheter-related infection recommendations: 2017 update. Perit Dial Int. 2017;37(2):141-154. doi:10.3747/pdi.2016.00120 [PubMed 28360365]
  214. Takimoto R, Honda T, Kataoka TR, Ueshima C, Otsuka A, Kabashima K. DIHS/DRESS-like eruption possibly induced by amoxicillin during treatment with nivolumab. Eur J Dermatol. 2019;29(2):228-229. doi:10.1684/ejd.2019.3522 [PubMed 30973334]
  215. Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:260928. doi:10.1155/2015/260928 [PubMed 26783390]
  216. Tikmani SS, Muhammad AA, Shafiq Y, et al. Ambulatory treatment of fast breathing in young infants aged <60 days: a double-blind, randomized, placebo-controlled equivalence trial in low-income settlements of Karachi. Clin Infect Dis. 2017;64(2):184-189. doi:10.1093/cid/ciw690 [PubMed 27941119]
  217. Tshefu A, Lokangaka A, African Neonatal Sepsis Trial (AFRINEST) group, et al. Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial. Lancet. 2015a;385(9979):1758-1766. doi:10.1016/S0140-6736(14)62285-6 [PubMed 25842223]
  218. Tshefu A, Lokangaka A, African Neonatal Sepsis Trial (AFRINEST) group, et al. Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet. 2015b;385(9979):1767-1776. doi:10.1016/S0140-6736(14)62284-4 [PubMed 25842221]
  219. Tu YH, Stiles ML, Allen LV Jr, et al. Stability of Amoxicillin Trihydrate-Potassium Clavulanate in Original Containers and Unit Dose Oral Syringes. Am J Hosp Pharm. 1988;45(5):1092-1099. [PubMed 3400652]
  220. Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist. 2014;7:183-197. doi:10.2147/IDR.S39601 [PubMed 25045274]
  221. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008 [PubMed 27216385]
  222. Varela VM, Heller D, Silva-Senem MX, et al. Systemic Antimicrobials Adjunctive to a Repeated Mechanical and Antiseptic Therapy for Aggressive Periodontitis: A 6-Month Randomized Controlled Trial. J Periodontol. 2011;82(8):1121-1130. [PubMed 21235333]
  223. Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics. 2013;132(1):e262-e280. [PubMed 23796742]
  224. Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int. 2012;32(suppl 2):S32-S86. [PubMed 22851742]
  225. Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset Clostridium difficile infections in a large healthcare system. Clin Infect Dis. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112 [PubMed 29272341]
  226. Weingärtner L, Sitka U, Patsch R, Richter I. Experience with amoxycillin in neonates and premature babies. Int J Clin Pharmacol Biopharm. 1977;15(4):184-188. [PubMed 870440]
  227. Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021;143(20):e963-e978. doi:10.1161/CIR.0000000000000969 [PubMed 33853363]
  228. Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis. Guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736-1754. [PubMed 17446442]
  229. World Health Organization (WHO). Mastitis: Causes and Management, Publication Number WHO/FCH/CAH/00.13. World Health Organization: Geneva, Switzerland; 2000.
  230. World Health Organization (WHO). WHO Model Prescribing Information: Drugs Used in Bacterial Infections. Geneva, Switzerland: World Health Organization; 2001. http://apps.who.int/medicinedocs/pdf/s5406e/s5406e.pdf. Accessed November 6, 2018.
  231. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/ [PubMed 23215911]
  232. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1 [PubMed 34292926]
  233. Wright AJ. The Penicillins. Mayo Clin Proc. 1999;74(3):290-307. [PubMed 10090000]
  234. Wynn RL. Amoxicillin Update. Gen Dent. 1991;39(5):322,4,6. [PubMed 1812049]
  235. Yang MS, Lee JY, Kim J, et al. Searching for the culprit drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea. J Allergy Clin Immunol Pract. 2020;8(2):690-695.e2. doi:10.1016/j.jaip.2019.09.032 [PubMed 31614216]
  236. Zareba-Szczudlik J, Romejko-Wolniewicz E, Lewandowski Z, et al. Evaluation of the amoxicillin concentrations in amniotic fluid, placenta, umbilical cord blood and maternal serum two hours after oral administration. Neuro Endocrinol Lett. 2017;38(7):502-508. [PubMed 29369602]
  237. Zhan Y, Si M, Li M, Jiang Y. The risk of Helicobacter pylori infection for adverse pregnancy outcomes: a systematic review and meta-analysis. Helicobacter. 2019;24(2):e12562. doi:10.1111/hel.12562 [PubMed 30672065]
  238. Zhou H, Xu Q, Liu Y, Guo LT. Risk factors, incidence, and morbidity associated with antibiotic-associated diarrhea in intensive care unit patients receiving antibiotic monotherapy. World J Clin Cases. 2020;8(10):1908-1915. doi:10.12998/wjcc.v8.i10.1908 [PubMed 32518780]
Topic 8673 Version 571.0